Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen

Hengstman, GJD; Egberts, WTMV; Seelig, HP; Lundberg, IE; Moutsopoulos, HM; Doria, A; Mosca, M; Vencovsky, J; van Venrooij, WJ; van Engelen, BGM

dc.contributor.author	Hengstman, GJD	en
dc.contributor.author	Egberts, WTMV	en
dc.contributor.author	Seelig, HP	en
dc.contributor.author	Lundberg, IE	en
dc.contributor.author	Moutsopoulos, HM	en
dc.contributor.author	Doria, A	en
dc.contributor.author	Mosca, M	en
dc.contributor.author	Vencovsky, J	en
dc.contributor.author	van Venrooij, WJ	en
dc.contributor.author	van Engelen, BGM	en
dc.date.accessioned	2014-03-01T01:55:30Z
dc.date.available	2014-03-01T01:55:30Z
dc.date.issued	2006	en
dc.identifier.issn	0003-4967	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27773
dc.subject.classification	Rheumatology	en
dc.subject.other	IDIOPATHIC INFLAMMATORY MYOPATHIES	en
dc.subject.other	DERMATOMYOSITIS	en
dc.subject.other	POLYMYOSITIS	en
dc.subject.other	ANTIBODIES	en
dc.subject.other	PROFILES	en
dc.subject.other	SERA	en
dc.title	Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2006	en
heal.abstract	Objectives: To assess the clinical implications of autoantibodies directed against different parts of the Mi-2 beta autoantigen in patients with myositis. Methods: A systematic assessment of the clinical, laboratory, and histological characteristics of 48 anti-Mi-2 positive patients from six European centres was made. Anti-Mi-2 autoantibodies were determined with an ELISA using four overlapping fragments spanning the entire amino acid sequence of the autoantigen. Data were compared with results for a large group of anti-Mi-2 negative patients with myositis published previously. Results: Anti-Mi-2 autoantibodies were found in dermatomyositis, polymyositis, and inclusion body myositis. In general, myositis with anti- Mi- 2 autoantibodies was characterised by relatively mild disease, sometimes accompanied by extramuscular symptoms, including arthralgia, arthritis, Raynaud's phenomenon, and interstitial lung disease. Cardiac disease was not seen, and treatment response was fair. No differences were found between patients with autoantibodies to different fragments of the Mi-2 beta antigen, except for a potentially increased risk of cancer in patients with antibodies directed to the N-terminal fragment of the autoantigen. Conclusions: Anti-Mi-2 autoantibodies are not a marker of a specific subtype of myositis. No significant differences between patients with autoantibodies to different fragments of the Mi-2 beta autoantigen are found, with the possible exception of an increased risk of cancer in patients with antibodies to the N- terminal fragment.	en
heal.publisher	B M J PUBLISHING GROUP	en
heal.journalName	ANNALS OF THE RHEUMATIC DISEASES	en
dc.identifier.isi	ISI:000234588900019	en
dc.identifier.volume	65	en
dc.identifier.issue	2	en
dc.identifier.spage	242	en
dc.identifier.epage	245	en